BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology
20 nov. 2019 07h00 HE
|
BrainStorm Cell Therapeutics Inc.
A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...
BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society
14 nov. 2019 07h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update
14 nov. 2019 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial...
BrainStorm Announces Grant of a New Japanese Patent for NurOwn®
13 nov. 2019 05h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
12 nov. 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
05 nov. 2019 06h15 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
28 oct. 2019 07h45 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
25 oct. 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
24 oct. 2019 08h45 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
23 oct. 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...